Joel A Sincavage

Array ( [id] => 6174381 [patent_doc_number] => 20020155084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-24 [patent_title] => 'Nanoemulsion formulations' [patent_app_type] => new [patent_app_number] => 09/867930 [patent_app_country] => US [patent_app_date] => 2001-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21444 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0155/20020155084.pdf [firstpage_image] =>[orig_patent_app_number] => 09867930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1309685 [patent_doc_number] => 06613521 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-09-02 [patent_title] => 'Molecules of the card-related protein family and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/865364 [patent_app_country] => US [patent_app_date] => 2001-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 24 [patent_no_of_words] => 57959 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/613/06613521.pdf [firstpage_image] =>[orig_patent_app_number] => 09865364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5791836 [patent_doc_number] => 20020162126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-31 [patent_title] => 'Methods and compositions for RNA interference' [patent_app_type] => new [patent_app_number] => 09/866557 [patent_app_country] => US [patent_app_date] => 2001-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 19781 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0162/20020162126.pdf [firstpage_image] =>[orig_patent_app_number] => 09866557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 472693 [patent_doc_number] => 07229974 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-06-12 [patent_title] => 'G cap-stabilized oligonucleotides' [patent_app_type] => utility [patent_app_number] => 09/860784 [patent_app_country] => US [patent_app_date] => 2001-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6657 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/229/07229974.pdf [firstpage_image] =>[orig_patent_app_number] => 09860784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1288039 [patent_doc_number] => 06632617 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-10-14 [patent_title] => 'Tumor-associated antigen' [patent_app_type] => B1 [patent_app_number] => 09/855288 [patent_app_country] => US [patent_app_date] => 2001-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 17932 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/632/06632617.pdf [firstpage_image] =>[orig_patent_app_number] => 09855288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6082417 [patent_doc_number] => 20020082230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-27 [patent_title] => 'Antisense oligomer' [patent_app_type] => new [patent_app_number] => 09/849014 [patent_app_country] => US [patent_app_date] => 2001-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6517 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0082/20020082230.pdf [firstpage_image] =>[orig_patent_app_number] => 09849014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1366065 [patent_doc_number] => 06566132 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-05-20 [patent_title] => 'Antisense modulation of Interferon gamma receptor 1 expression' [patent_app_type] => B1 [patent_app_number] => 09/843376 [patent_app_country] => US [patent_app_date] => 2001-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30351 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/566/06566132.pdf [firstpage_image] =>[orig_patent_app_number] => 09843376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1164420 [patent_doc_number] => 06756196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-06-29 [patent_title] => 'Molecules of the card-related protein family and uses thereof' [patent_app_type] => B2 [patent_app_number] => 09/841879 [patent_app_country] => US [patent_app_date] => 2001-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 38412 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/756/06756196.pdf [firstpage_image] =>[orig_patent_app_number] => 09841879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6112624 [patent_doc_number] => 20020173475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-21 [patent_title] => 'Methods to inhibit viral replication' [patent_app_type] => new [patent_app_number] => 09/836073 [patent_app_country] => US [patent_app_date] => 2001-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5108 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0173/20020173475.pdf [firstpage_image] =>[orig_patent_app_number] => 09836073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5985044 [patent_doc_number] => 20020098162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-07-25 [patent_title] => 'Remedy and preventive for diseases caused by NF-kappaB' [patent_app_type] => new [patent_app_number] => 09/832841 [patent_app_country] => US [patent_app_date] => 2001-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3294 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20020098162.pdf [firstpage_image] =>[orig_patent_app_number] => 09832841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6083078 [patent_doc_number] => 20020082415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-27 [patent_title] => 'Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression' [patent_app_type] => new [patent_app_number] => 09/825497 [patent_app_country] => US [patent_app_date] => 2001-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10963 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0082/20020082415.pdf [firstpage_image] =>[orig_patent_app_number] => 09825497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7078354 [patent_doc_number] => 20010041337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-11-15 [patent_title] => 'Specific inhibitors of DNA methyltransferase' [patent_app_type] => new [patent_app_number] => 09/824308 [patent_app_country] => US [patent_app_date] => 2001-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 7241 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0041/20010041337.pdf [firstpage_image] =>[orig_patent_app_number] => 09824308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6612342 [patent_doc_number] => 20020064557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-05-30 [patent_title] => 'Microencapsulation and sustained release of oligonucleotides' [patent_app_type] => new [patent_app_number] => 09/820587 [patent_app_country] => US [patent_app_date] => 2001-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 8270 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20020064557.pdf [firstpage_image] =>[orig_patent_app_number] => 09820587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5829188 [patent_doc_number] => 20020068711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-06 [patent_title] => 'Arrest of proliferation of highly glycolytic tumors' [patent_app_type] => new [patent_app_number] => 09/808743 [patent_app_country] => US [patent_app_date] => 2001-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15260 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0068/20020068711.pdf [firstpage_image] =>[orig_patent_app_number] => 09808743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 435918 [patent_doc_number] => 07262175 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-08-28 [patent_title] => 'Synthetic oligonucleotides as inducers of erythroid differentiation' [patent_app_type] => utility [patent_app_number] => 10/220310 [patent_app_country] => US [patent_app_date] => 2001-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1979 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/262/07262175.pdf [firstpage_image] =>[orig_patent_app_number] => 10220310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6567809 [patent_doc_number] => 20020165174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-07 [patent_title] => 'Methods and compositions for antisense VEGF oligonucleotides' [patent_app_type] => new [patent_app_number] => 09/805761 [patent_app_country] => US [patent_app_date] => 2001-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 24740 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20020165174.pdf [firstpage_image] =>[orig_patent_app_number] => 09805761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6082406 [patent_doc_number] => 20020082228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-06-27 [patent_title] => 'Antisense modulation of BH3 interacting domain death agonist expression' [patent_app_type] => new [patent_app_number] => 09/800631 [patent_app_country] => US [patent_app_date] => 2001-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27614 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0082/20020082228.pdf [firstpage_image] =>[orig_patent_app_number] => 09800631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1550067 [patent_doc_number] => 06399378 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-04 [patent_title] => 'Antisense modulation of RECQL2 expression' [patent_app_type] => B1 [patent_app_number] => 09/798096 [patent_app_country] => US [patent_app_date] => 2001-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24774 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/399/06399378.pdf [firstpage_image] =>[orig_patent_app_number] => 09798096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6403251 [patent_doc_number] => 20020037315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-03-28 [patent_title] => 'Alzheimer\'s disease secretase, APP substrates therefor, and uses therefor' [patent_app_type] => new [patent_app_number] => 09/794748 [patent_app_country] => US [patent_app_date] => 2001-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 28352 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0037/20020037315.pdf [firstpage_image] =>[orig_patent_app_number] => 09794748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1315168 [patent_doc_number] => 06607916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2003-08-19 [patent_title] => 'Antisense inhibition of Casein kinase 2-alpha expression' [patent_app_type] => B2 [patent_app_number] => 09/780172 [patent_app_country] => US [patent_app_date] => 2001-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37880 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/607/06607916.pdf [firstpage_image] =>[orig_patent_app_number] => 09780172 [rel_patent_id] =>[rel_patent_doc_number] =>)